Integra LifeSciences Holdings Co (NASDAQ: IART) suffers from meaningful negative changes in fundamentals: significant quarterly sales deceleration occurred, the consensus estimate for December, 2024 decreased significantly, and the consensus estimate for December, 2025 decreased significantly.
Recent exceptional negative changes in investment behavior have affected Integra LifeSciences Holdings Co (NASDAQ: IART): negative upside/downside volume developed, and the stock fell on very heavy volume.
In light of these highly negative signals we are reviewing our current Overall Rating of C. We would view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, IART is expected to continue to be an important Value Builder.
Integra LifeSciences Holdings has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Integra LifeSciences Holdings has a slightly positive Appreciation Score of 61 but a slightly negative Power Rating of 37, leading to the Low Neutral Value Trend Rating.
Recent Price Action
Integra LifeSciences Holdings Co (NASDAQ: IART) stock closed at $35.88 on 3/12/24 after a slight decline of -0.9%. Moreover, trading volume in this decline was exceptionally high at 215% of normal. The stock is unchanged during the last week and has performed in line with the market over the last nine months.
Be the first to comment